Literature DB >> 27296591

Unique medical issues in adult patients with mucopolysaccharidoses.

John Mitchell1, Kenneth I Berger2, Andrea Borgo3, Elizabeth A Braunlin4, Barbara K Burton5, Kemel A Ghotme6, Susanne G Kircher7, David Molter8, Paul J Orchard9, James Palmer10, Gregory M Pastores11, David M Rapoport12, Raymond Y Wang13, Klane White14.   

Abstract

The mucopolysaccharidoses are a group of inherited metabolic diseases caused by deficiencies in enzymes involved in the sequential degradation of glycosaminoglycans (GAGs) leading to substrate accumulation in various tissues and organs. GAG accumulation can cause growth retardation and progressive damage to respiratory, cardiovascular, musculoskeletal, nervous, gastrointestinal, auditory, and visual systems. In the past, few people with severe phenotypic mucopolysaccharidosis (MPS) reached adulthood. However, better methods for diagnosis, multi-disciplinary care, and new therapies have extended lifespan, leading to an increasing number of patients surviving beyond childhood. The growing number of adult MPS patients poses significant challenges for clinicians who may not be familiar with the clinical manifestations of MPS. In addition, as new interventions have changed the natural history of these disorders, it is difficult to anticipate both the impact on life expectancy and other complications that may occur as these patients age. Because the MPS disorders are multi-organ diseases, their management requires a coordinated multi-disciplinary approach. Here we discuss the unique pattern of medical issues and multi-organ involvement in adult patients with MPS and identify the challenges that are associated with management of MPS. This review is based on information from an expert investigator meeting with MPS specialists held October 2-4, 2014 in Dublin, Ireland, as well as on current literature searches focusing on MPS and adults.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adult; Disease management; Enzyme replacement therapy; Lysosomal storage diseases; Mucopolysaccharidoses; Review

Mesh:

Substances:

Year:  2016        PMID: 27296591     DOI: 10.1016/j.ejim.2016.05.017

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  15 in total

1.  Spinal cord issues in adult patients with MPS: transition of care survey.

Authors:  Kemel A Ghotme; Fernando Alvarado-Gomez; Christina Lampe; Klane K White; Martha Solano-Villareal; Roberto Giugliani; Paul R Harmatz
Journal:  Childs Nerv Syst       Date:  2018-05-27       Impact factor: 1.475

2.  Natural History and Molecular Characteristics of Korean Patients with Mucopolysaccharidosis Type III.

Authors:  Min-Sun Kim; Aram Yang; Eu-Seon Noh; Chiwoo Kim; Ga Young Bae; Han Hyuk Lim; Hyung-Doo Park; Sung Yoon Cho; Dong-Kyu Jin
Journal:  J Pers Med       Date:  2022-04-21

3.  Mucopolysaccharidoses diagnosis in the era of enzyme replacement therapy in Egypt.

Authors:  Ekram Fateen; Zeinab Y Abdallah; Walaa S Nazim; Mona Ibrahim; Amira Radwan
Journal:  Heliyon       Date:  2021-08-19

4.  The Carotid Intima-Media Thickness and Arterial Stiffness of Pediatric Mucopolysaccharidosis Patients Are Increased Compared to Both Pediatric and Adult Controls.

Authors:  Raymond Y Wang; Kyle D Rudser; Donald R Dengel; Elizabeth A Braunlin; Julia Steinberger; David R Jacobs; Alan R Sinaiko; Aaron S Kelly
Journal:  Int J Mol Sci       Date:  2017-03-15       Impact factor: 5.923

5.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

6.  Transition of patients with mucopolysaccharidosis from paediatric to adult care.

Authors:  C Lampe; B McNelly; A K Gevorkian; C J Hendriksz; T V Lobzhanidze; J Pérez-López; K M Stepien; N D Vashakmadze; M Del Toro
Journal:  Mol Genet Metab Rep       Date:  2019-10-21

7.  Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome-Type II Mucopolysaccharidosis.

Authors:  Hantai Kim; Jun Young An; Oak-Sung Choo; Jeong Hun Jang; Hun Yi Park; Yun-Hoon Choung
Journal:  J Audiol Otol       Date:  2019-12-10

8.  Mortality in patients with Sanfilippo syndrome.

Authors:  Christine Lavery; Chris J Hendriksz; Simon A Jones
Journal:  Orphanet J Rare Dis       Date:  2017-10-23       Impact factor: 4.123

9.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

Review 10.  Orthopaedic challenges for mucopolysaccharidoses.

Authors:  Andrea Borgo; Andrea Cossio; Denise Gallone; Francesca Vittoria; Marco Carbone
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.